GlassScriptPhysician profile
Faheem Ahmad
NPI 1942282215
$5,880.95
in general payments reported to CMS, 2019-2025
26 companies · $1,573 in 2025
The $1,573 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $159 · 2021: $302 · 2022: $2,243 · 2023: $469 · 2024: $129 · 2025: $1,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398 · Travel and Lodging: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.98 |
| Travel and Lodging | $773.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,816.40 | 2022 | |
| Philips North America LLC | $1,311.79 | 2025 | Coronary Other, Coronary Undivided |
| Boston Scientific Corporation | $651.64 | 2019-2024 | Watchman Access System, Ranger, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $278.62 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $271.20 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $268.18 | 2019-2024 | |
| Shockwave Medical, INC | $186.54 | 2021-2025 | |
| Abbott Laboratories | $182.98 | 2021 | |
| Edwards Lifesciences Corporation | $160.14 | 2019-2025 | Pascal |
| Inari Medical, INC. | $116.00 | 2022 | |
| Medicure Pharma INC. | $110.51 | 2019 | |
| Esperion Therapeutics, INC. | $75.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $65.06 | 2019 | |
| Sanofi-Aventis U.S. LLC | $62.47 | 2019 | |
| Medtronic, INC. | $47.48 | 2022-2023 | Hawkone |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.87 | 2020 | |
| Amgen INC. | $37.83 | 2019-2025 | Repatha |
| Abiomed | $37.29 | 2024 | Impella |
| Allergan, INC. | $35.87 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.20 | 2019-2020 | |
| Heartflow, INC. | $23.03 | 2025 | |
| Novo Nordisk INC | $22.83 | 2023 | Ozempic |
| Gilead Sciences, INC. | $21.99 | 2019 | |
| Ekos Corporation | $16.38 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.00 | 2019 | |
| Cardiovascular Systems INC. | $2.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faheem Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.